FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies

Ben W. Mol; Bo Jacobsson; William Grobman; Kelle Moley; FIGO Working Group for Preterm Birth

doi:10.1002/ijgo.13834

FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies

Ben W. Mol, Bo Jacobsson, William Grobman, Kelle Moley, FIGO Working Group for Preterm Birth

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

2 Downloads (Pure)

Abstract

FIGO (the International Federation of Gynecology and Obstetrics) supports assisted reproductive technologies (ART) to achieve pregnancy and supports their availability in all nations. However, the increased frequency of preterm birth must be taken into account. Therefore, before in vitro fertilization (IVF) is started, other approaches, including expectant management, should be considered. Single embryo transfer is the best approach to ensure a live, healthy child. However, increased risks for preterm birth are also associated with a singleton IVF pregnancy and should be discussed and contrasted with spontaneous conception. Increased preterm birth and other adverse pregnancy outcomes in singleton IVF cycles warrant investigations to elucidate and mitigate. Minimizing embryo manipulation during cell culture is recommended. Increased risk of preterm birth and other pregnancy complications in ART could reflect the underlying reasons for infertility. This information should be discussed and further explored.

Original language	English
Pages (from-to)	13-15
Number of pages	3
Journal	International Journal of Gynecology and Obstetrics
Volume	155
Issue number	1
Early online date	14 Sept 2021
DOIs	https://doi.org/10.1002/ijgo.13834
Publication status	Published - 1 Oct 2021

Bibliographical note

Funding Information:
This work has been supported by grants from March of Dimes to the FIGO Working Group for Preterm Birth. This document is endorsed by FIGO Committee for Reproductive Medicine, Endocrinology and Infertility, and was discussed at their committee meeting on March 11, 2021.

Funding Information:
Ben W. Mol reports an investigator grant from NHMRC; consultancy for ObsEva; and research funding from Guerbet, Ferring, and Merck KGaA. Bo Jacobbson reports Research grants from Swedish Research Council, Norwegian Research Council, March of Dimes, Burroughs Wellcome Fund and the US National Institute of Health; clinical diagnostic trials on NIPT with Ariosa (completed), Natera (ongoing), Vanadis (completed) and Hologic (ongoing) with expendidures reimbused per patient; clinical probiotic studies with product provided by FukoPharma (ongoing, no funding) and BioGaia (ongoing; also provided a research grant for the specific study); collaboration in IMPACT study where Roche, Perkin Elmer and Thermo Fisher provided reagents to PLGF analyses; coordination of scientific conferences and meetings with commercial partners as such as NNFM 2015, ESPBC 2016 and a Nordic educational meeting about NIPT and preeclampsia screening. Bo Jacobbson is also Chair of the FIGO Working Group for Preterm Birth and the European Association of Perinatal Medicine's special interest group of preterm delivery; steering group member of Genomic Medicine Sweden; chairs the Genomic Medicine Sweden complex diseases group; and is Swedish representative in the Nordic Society of Precision Medicine. William Grobman and Kelle Moley report no conflicts of interest.

Keywords

assisted reproductive technology
child outcome
preterm delivery
single embryo transfer

Access to Document

10.1002/ijgo.13834Licence: CC BY

Mol_etal_GO_FIGO_goog_practice_VOR
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.https://creativecommons.org/licenses/by/4.0/
Final published version, 336 KBLicence: CC BY

Cite this

@article{b9a0e77b8d0242518243ab75dc360a97,

title = "FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies",

abstract = "FIGO (the International Federation of Gynecology and Obstetrics) supports assisted reproductive technologies (ART) to achieve pregnancy and supports their availability in all nations. However, the increased frequency of preterm birth must be taken into account. Therefore, before in vitro fertilization (IVF) is started, other approaches, including expectant management, should be considered. Single embryo transfer is the best approach to ensure a live, healthy child. However, increased risks for preterm birth are also associated with a singleton IVF pregnancy and should be discussed and contrasted with spontaneous conception. Increased preterm birth and other adverse pregnancy outcomes in singleton IVF cycles warrant investigations to elucidate and mitigate. Minimizing embryo manipulation during cell culture is recommended. Increased risk of preterm birth and other pregnancy complications in ART could reflect the underlying reasons for infertility. This information should be discussed and further explored.",

keywords = "assisted reproductive technology, child outcome, preterm delivery, single embryo transfer",

author = "Mol, {Ben W.} and Bo Jacobsson and William Grobman and Kelle Moley and Mol, {Ben W.} and Bo Jacobsson and Simpson, {Joe Leigh} and Jane Norman and William Grobman and Ana Bianchi and Stephen Munjanja and Gonz{\'a}lez, {Catalina Mar{\'i}a Valencia} and Andrew Shennan and {FIGO Working Group for Preterm Birth}",

note = "Funding Information: This work has been supported by grants from March of Dimes to the FIGO Working Group for Preterm Birth. This document is endorsed by FIGO Committee for Reproductive Medicine, Endocrinology and Infertility, and was discussed at their committee meeting on March 11, 2021. Funding Information: Ben W. Mol reports an investigator grant from NHMRC; consultancy for ObsEva; and research funding from Guerbet, Ferring, and Merck KGaA. Bo Jacobbson reports Research grants from Swedish Research Council, Norwegian Research Council, March of Dimes, Burroughs Wellcome Fund and the US National Institute of Health; clinical diagnostic trials on NIPT with Ariosa (completed), Natera (ongoing), Vanadis (completed) and Hologic (ongoing) with expendidures reimbused per patient; clinical probiotic studies with product provided by FukoPharma (ongoing, no funding) and BioGaia (ongoing; also provided a research grant for the specific study); collaboration in IMPACT study where Roche, Perkin Elmer and Thermo Fisher provided reagents to PLGF analyses; coordination of scientific conferences and meetings with commercial partners as such as NNFM 2015, ESPBC 2016 and a Nordic educational meeting about NIPT and preeclampsia screening. Bo Jacobbson is also Chair of the FIGO Working Group for Preterm Birth and the European Association of Perinatal Medicine's special interest group of preterm delivery; steering group member of Genomic Medicine Sweden; chairs the Genomic Medicine Sweden complex diseases group; and is Swedish representative in the Nordic Society of Precision Medicine. William Grobman and Kelle Moley report no conflicts of interest. ",

year = "2021",

month = oct,

day = "1",

doi = "10.1002/ijgo.13834",

language = "English",

volume = "155",

pages = "13--15",

journal = "International Journal of Gynecology and Obstetrics",

issn = "0020-7292",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies

AU - Mol, Ben W.

AU - Jacobsson, Bo

AU - Grobman, William

AU - Moley, Kelle

AU - Mol, Ben W.

AU - Jacobsson, Bo

AU - Simpson, Joe Leigh

AU - Norman, Jane

AU - Grobman, William

AU - Bianchi, Ana

AU - Munjanja, Stephen

AU - González, Catalina María Valencia

AU - Shennan, Andrew

AU - FIGO Working Group for Preterm Birth

N1 - Funding Information: This work has been supported by grants from March of Dimes to the FIGO Working Group for Preterm Birth. This document is endorsed by FIGO Committee for Reproductive Medicine, Endocrinology and Infertility, and was discussed at their committee meeting on March 11, 2021. Funding Information: Ben W. Mol reports an investigator grant from NHMRC; consultancy for ObsEva; and research funding from Guerbet, Ferring, and Merck KGaA. Bo Jacobbson reports Research grants from Swedish Research Council, Norwegian Research Council, March of Dimes, Burroughs Wellcome Fund and the US National Institute of Health; clinical diagnostic trials on NIPT with Ariosa (completed), Natera (ongoing), Vanadis (completed) and Hologic (ongoing) with expendidures reimbused per patient; clinical probiotic studies with product provided by FukoPharma (ongoing, no funding) and BioGaia (ongoing; also provided a research grant for the specific study); collaboration in IMPACT study where Roche, Perkin Elmer and Thermo Fisher provided reagents to PLGF analyses; coordination of scientific conferences and meetings with commercial partners as such as NNFM 2015, ESPBC 2016 and a Nordic educational meeting about NIPT and preeclampsia screening. Bo Jacobbson is also Chair of the FIGO Working Group for Preterm Birth and the European Association of Perinatal Medicine's special interest group of preterm delivery; steering group member of Genomic Medicine Sweden; chairs the Genomic Medicine Sweden complex diseases group; and is Swedish representative in the Nordic Society of Precision Medicine. William Grobman and Kelle Moley report no conflicts of interest.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - FIGO (the International Federation of Gynecology and Obstetrics) supports assisted reproductive technologies (ART) to achieve pregnancy and supports their availability in all nations. However, the increased frequency of preterm birth must be taken into account. Therefore, before in vitro fertilization (IVF) is started, other approaches, including expectant management, should be considered. Single embryo transfer is the best approach to ensure a live, healthy child. However, increased risks for preterm birth are also associated with a singleton IVF pregnancy and should be discussed and contrasted with spontaneous conception. Increased preterm birth and other adverse pregnancy outcomes in singleton IVF cycles warrant investigations to elucidate and mitigate. Minimizing embryo manipulation during cell culture is recommended. Increased risk of preterm birth and other pregnancy complications in ART could reflect the underlying reasons for infertility. This information should be discussed and further explored.

AB - FIGO (the International Federation of Gynecology and Obstetrics) supports assisted reproductive technologies (ART) to achieve pregnancy and supports their availability in all nations. However, the increased frequency of preterm birth must be taken into account. Therefore, before in vitro fertilization (IVF) is started, other approaches, including expectant management, should be considered. Single embryo transfer is the best approach to ensure a live, healthy child. However, increased risks for preterm birth are also associated with a singleton IVF pregnancy and should be discussed and contrasted with spontaneous conception. Increased preterm birth and other adverse pregnancy outcomes in singleton IVF cycles warrant investigations to elucidate and mitigate. Minimizing embryo manipulation during cell culture is recommended. Increased risk of preterm birth and other pregnancy complications in ART could reflect the underlying reasons for infertility. This information should be discussed and further explored.

KW - assisted reproductive technology

KW - child outcome

KW - preterm delivery

KW - single embryo transfer

UR - http://www.scopus.com/inward/record.url?scp=85115059244&partnerID=8YFLogxK

U2 - 10.1002/ijgo.13834

DO - 10.1002/ijgo.13834

M3 - Article

AN - SCOPUS:85115059244

SN - 0020-7292

VL - 155

SP - 13

EP - 15

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

IS - 1

ER -

FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this